Jagsonpal Pharmaceuticals announced strong financial results for FY25, with revenue reaching 2,687 million (up 28.8% YoY) and an operating EBITDA of 579 million, along with a recommended 125% dividend. This press release was made on May 6, 2025, summarizing the company's fiscal performance for the year ended March 31, 2025.